Skip to Content

SnET2-PDT Approval Status

  • FDA approved: No
  • Brand name: SnET2-PDT
  • Generic name: Tin ethyl etiopurpurin (SnET2) photodynamic therapy (PDT)
  • Company: Miravant
  • Treatment for: Macular Degeneration

Development Status and FDA Approval Process for SnET2-PDT

DateArticle
Jun  1, 2004Miravant's SnET2 New Drug Application Accepted for Filing by FDA with Priority Review Designation
Mar 31, 2004Miravant Submits New Drug Application For SnET2-PDT to Treat Macular Degeneration

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide